Physician profile
Lin Z Johnson
NPI 1104801737
$3,329.19
in general payments reported to CMS, 2019-2025
23 companies · $17.19 in 2025
The $17.19 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $419 · 2020: $147 · 2021: $860 · 2022: $825 · 2023: $787 · 2024: $275 · 2025: $17.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056 · Education: $21.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.42 |
| Education | $21.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $560.40 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $539.27 | 2019-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $338.29 | 2019-2023 | Jynarque |
| Aurinia Pharma U.S., INC. | $314.16 | 2021-2024 | Lupkynis |
| Amgen INC. | $259.42 | 2021-2024 | Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $243.00 | 2019-2023 | Rayaldee |
| Horizon Therapeutics Plc | $166.45 | 2019-2022 | |
| Akebia Therapeutics INC | $142.22 | 2019-2024 | Vafseo, Auryxia |
| Abbott Laboratories | $112.75 | 2022 | |
| Glaxosmithkline, LLC. | $98.01 | 2021-2022 | |
| Travere Therapeutics, INC. | $82.53 | 2020-2023 | |
| Mallinckrodt Hospital Products INC. | $80.88 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.85 | 2021 | |
| Fresenius USA Marketing, INC. | $52.99 | 2023-2024 | Velphoro, Korsuva |
| Amag Pharmaceuticals, INC. | $52.99 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.35 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.13 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $35.91 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $31.10 | 2021-2023 | Soliris |
| Nxstage Medical, INC. | $26.97 | 2021 | |
| Scpharmaceuticals INC. | $17.19 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.73 | 2024 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.